Literature DB >> 8287280

Amyloid beta-protein stimulates casein kinase I and casein kinase II activities.

A Chauhan1, V P Chauhan, N Murakami, H Brockerhoff, H M Wisniewski.   

Abstract

Amyloid beta-protein (A beta) is the major protein of cerebrovascular and plaque amyloid in Alzheimer's disease (AD). Extensive evidence has demonstrated abnormal protein phosphorylation in this disease. We investigated the effect of synthetic A beta with the amino-acid sequence corresponding to cerebrovascular A beta and plaque A beta on the activities of casein kinase I (CK I) and casein kinase II (CK II). These enzymes were purified from bovine brain and casein was used as a substrate. A beta was found to stimulate markedly CK I- and CK II-mediated phosphorylation of casein in a concentration-dependent manner. The effect of plaque A beta was considerably higher than that of cerebrovascular A beta. Heparin, which is known to be a specific inhibitor of CK II, completely inhibited A beta-stimulated CK II activity. A beta itself was not a substrate for casein kinases. These findings were confirmed using other substrates for CK I and CK II. The experiments with synthetic CK II-substrate peptide (Leu-Glu-Leu-Ser-Asp-Asp-Asp-Asp-Glu) and the phosphorylation of erythrocyte membrane proteins by intrinsic membrane-bound CK I in erythrocytes showed marked stimulation in activities of casein kinases in the presence of A beta 1-40 or blocked A beta. We propose that A beta, by stimulating casein kinases, may contribute to abnormal protein phosphorylation in AD, in particular to increased phosphorylation of microtubule-associated proteins, leading to the neurofibrillary tangles formation and neurodegeneration in this disease. Interaction of A beta with protein kinases, thus, may characterize the beginning of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8287280     DOI: 10.1016/0006-8993(93)90479-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Sublethal doses of β-amyloid peptide abrogate DNA-dependent protein kinase activity.

Authors:  Alessio Cardinale; Mauro Racaniello; Serena Saladini; Giovanna De Chiara; Cristiana Mollinari; Maria Chiara de Stefano; Maurizio Pocchiari; Enrico Garaci; Daniela Merlo
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

2.  Binding of amyloid beta-protein to intracellular brain proteins in rat and human.

Authors:  I Ray; A Chauhan; H M Wisniewski; J Wegiel; K S Kim; V P Chauhan
Journal:  Neurochem Res       Date:  1998-10       Impact factor: 3.996

3.  Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta.

Authors:  G Pigino; G Morfini; Y Atagi; A Deshpande; C Yu; L Jungbauer; M LaDu; J Busciglio; S Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

Review 4.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

5.  Inhibition of casein kinase 2 modulates XBP1-GRP78 arm of unfolded protein responses in cultured glial cells.

Authors:  Toru Hosoi; Kenta Korematsu; Naohiro Horie; Takahiro Suezawa; Yasunobu Okuma; Yasuyuki Nomura; Koichiro Ozawa
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 6.  The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis.

Authors:  Uwe Knippschild; Marc Krüger; Julia Richter; Pengfei Xu; Balbina García-Reyes; Christian Peifer; Jakob Halekotte; Vasiliy Bakulev; Joachim Bischof
Journal:  Front Oncol       Date:  2014-05-19       Impact factor: 6.244

Review 7.  Protein phosphorylation in neurodegeneration: friend or foe?

Authors:  Sandra Tenreiro; Katrin Eckermann; Tiago F Outeiro
Journal:  Front Mol Neurosci       Date:  2014-05-13       Impact factor: 5.639

8.  Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells.

Authors:  Melanie Bender; Lisa Schwind; David Grundmann; Monika Martin; Markus Klotz; Claudia Götz; Mathias Montenarh; Karl-Herbert Schäfer
Journal:  Heliyon       Date:  2017-06-09

Review 9.  CK2-An Emerging Target for Neurological and Psychiatric Disorders.

Authors:  Julia Castello; Andre Ragnauth; Eitan Friedman; Heike Rebholz
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-05

10.  CK1δ-Derived Peptides as Novel Tools Inhibiting the Interactions between CK1δ and APP695 to Modulate the Pathogenic Metabolism of APP.

Authors:  Aileen Roth; Fabian Gärtner; Katja Mayer; Julian Beyrle; Irina König; Uwe Knippschild; Joachim Bischof
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.